Nicholas C Smith, Tanae’Ja C Burroughs, Patric H Gaspard, Nandi P Okonkwo, Duy P Tran, Phyllisity V Walters, PharmD Candidates; Jocelyn D. Spates, PharmD, BCPS

Aducanumab-avwa is a monoclonal antibody that is the first treatment of its class designed to target the amyloid β protein, a biomarker of Alzheimer disease and other dementias.